Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results
I'm PortAI, I can summarize articles.
Analyst Andrew Fein from H.C. Wainwright maintains a Buy rating on AC Immune SA, with a price target of $12.00, due to promising advancements in Parkinson’s treatment. AC Immune's ACI-7104 vaccine shows groundbreaking results, including a 100% responder rate and significant stabilization of neurofilament light chain levels, indicating potential disease modification and accelerated development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments